Wednesday, September 23, 2020

Libra Therapeutics Nabs $29M For Neurodegenerative Disease Treatments

San Diego-based Libra Therapeutics, a new startup developing treatments for various neurodegenerative diseases, has raised $29M in its Series A funding round, the company said this morning. According to Libra Therapeutics, the funding was co-led by Boehringer Ingelheim Venture Fund (BIVF), Epidarex Capital, and Sante, and also included Yonjin Venture, Dolby Family Ventures, and Sixty Degree Capital. The company said it is looking to treat such diseases as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The company also said it has named Issac Veinbergs, Ph.D., as its new President and CEO.